Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients

Table 2

Combined treatment group parameters of patients at the beginning and at the end of the study.

Parameters	Beginning ()	End ()	P
FBG (mmol/L)	7.14 ± 1.39	6.38 ± 1.31	0.04
SBP (mmHg)	132.36 ± 15.52	133.35 ± 18.70	0.83
HbA1c (%)	7.32 ± 0.91	6.64 ± 1.08	0.02
BMI (kg/m^2)	29.53 ± 2.02	28.63 ± 1.51	0.07
TC (mmol/L)	4.50 ± 0.64	4.35 ± 0.57	0.37
TG (mmol/L)	2.23 ± 1.81	2.06 ± 1.66	0.72
NHDL (mmol/L)	3.89 ± 0.85	3.25 ± 1.10	0.03
HDL (mmol/L)	1.01 ± 0.24	1.08 ± 0.28	0.46
LDL (mmol/L)	2.64 ± 0.76	2.36 ± 0.67	0.18
UA (μmol/L)	351.18 ± 87.69	345.35 ± 79.11	0.80
IMT (mm)	1.27 ± 0.12	1.15 ± 0.15	0.05
Cr (μmol/L)	87.29 ± 12.72	90.31 ± 11.65	0.37
IL-6 (pg/mL)	18.70 ± 5.28	15.18 ± 5.18	0.02
ADPN (ng/mL)	11.02 ± 3.40	11.93 ± 3.40	0.33